Rhumbline Advisers Genetic Technologies LTD Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2023
BUY
$0.8 - $1.13 $14,960 - $21,130
18,700 New
18,700 $15,000

About GENETIC TECHNOLOGIES LTD

GENE Quotes by TradingView
  • Ticker GENE
  • Exchange OTC
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 15,389,900
  • Market Cap $11.9M
  • Description
  • Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...
More about GENE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email